Temozolomide in malignant gliomas: current use and future targets
- 19 June 2009
- journal article
- review article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 64 (4), 647-655
- https://doi.org/10.1007/s00280-009-1050-5
Abstract
Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ—mechanism of action, scheduling and strategies for overcoming resistance.Keywords
This publication has 56 references indexed in Scilit:
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- New (alternative) temozolomide regimens for the treatment of gliomaNeuro-Oncology, 2009
- A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancerBritish Journal of Cancer, 2008
- The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1Neuro-Oncology, 2007
- Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1Neuro-Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Cerebral Radiation NecrosisThe Neurologist, 2003
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000